AstraZeneca workers to strike
Members of a UK trade union working at AstraZeneca have voted to strike following cuts in pension benefits.
Members of a UK trade union working at AstraZeneca have voted to strike following cuts in pension benefits. According to a statement from UK trade union GMB, 70% of voters in a ballot supported the call for strike action. There will now be a meeting to fix dates unless AstraZeneca “come back to the negotiating table with meaningful terms”, said GMB.
The dispute stems from AstraZeneca’s proposals to change its pension scheme for approximately 2500 staff, based mainly at the company’s Macclesfield (UK) site. In a July statement released prior to the ballot, GMB claimed to have more than 600 members employed at the site. The union also added that the last 4 years have seen huge job losses at the site as well as “radical” changes in working practices.
“AstraZeneca has in financial terms done extremely well in recent years, last year operating profit rose by a staggering 24% compared to 2008. The first quarter of this year (2010) shows further growth year on year of 11% and hence our members see no financial need for these swingeing pension cuts,” said the GMB’s July statement.
According to GMB, talks about AstraZeneca’s pension proposals were held over a 3-month period earlier this year but the company has not moved from its original stance. GMB says it has enlisted the support of unions across Europe.
AstraZeneca have not yet released a press statement. However, an article from Reuters claims that AstraZeneca is reviewing the ballot and has said that about a third of GMB members and less than 2% of its UK employees voted in favour of the strike.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
